TY  - JOUR
AU  - Makhov, V. N.
AU  - Kirm, M.
AU  - Stryganyuk, G.
AU  - Vielhauer, S.
AU  - Zimmerer, G.
AU  - DESY
TI  - VUV luminescence due to 5d-4f transitions in Gd<sup>3+</sup> and Lu<sup>3+</sup> ions doped into fluoride crystals
JO  - ECS transactions
VL  - 11
SN  - 1938-5862
CY  - Pennington, NJ
PB  - Electrochemical Society (ECS)
M1  - PHPPUBDB-8392
SP  - 1-10
PY  - 2008
AB  - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0
KW  - Adolescent
KW  - Adult
KW  - Anticonvulsants: therapeutic use
KW  - Child
KW  - Child, Preschool
KW  - Double-Blind Method
KW  - Drug Evaluation
KW  - Drug Therapy, Combination: methods
KW  - Epilepsy: drug therapy
KW  - Female
KW  - Humans
KW  - Longitudinal Studies
KW  - Male
KW  - Treatment Outcome
KW  - Triazoles: therapeutic use
KW  - Young Adult
KW  - Anticonvulsants (NLM Chemicals)
KW  - Triazoles (NLM Chemicals)
KW  - rufinamide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:20199521
UR  - <Go to ISI:>//WOS:00
DO  - DOI:10.1149/1.2929812
UR  - https://bib-pubdb1.desy.de/record/84831
ER  -